QRG Capital Management Inc. Raises Position in Sanofi (NASDAQ:SNY)

QRG Capital Management Inc. grew its stake in shares of Sanofi (NASDAQ:SNY) by 8.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 152,406 shares of the company’s stock after buying an additional 12,245 shares during the quarter. QRG Capital Management Inc.’s holdings in Sanofi were worth $8,783,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its holdings in Sanofi by 773.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock worth $275,000 after acquiring an additional 5,004 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Sanofi by 7.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,618 shares of the company’s stock valued at $2,411,000 after purchasing an additional 3,268 shares during the period. Jennison Associates LLC raised its position in Sanofi by 18.9% during the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after purchasing an additional 30,115 shares during the last quarter. Financial Counselors Inc. lifted its holdings in Sanofi by 12.6% in the 1st quarter. Financial Counselors Inc. now owns 8,851 shares of the company’s stock worth $430,000 after buying an additional 993 shares during the period. Finally, Callan Capital LLC bought a new stake in shares of Sanofi in the 1st quarter worth approximately $251,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the subject of several research analyst reports. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 30th. Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $57.50.

Sanofi Price Performance

SNY opened at $52.95 on Tuesday. Sanofi has a 1 year low of $45.00 and a 1 year high of $58.97. The stock has a 50-day moving average price of $55.85 and a 200-day moving average price of $52.10. The firm has a market cap of $134.38 billion, a PE ratio of 27.02, a P/E/G ratio of 1.36 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the firm posted $2.55 EPS. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. Sell-side analysts predict that Sanofi will post 4.27 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.